BridgeBio Oncology Therapeutics (BBOT): Valuation
TTM figures as of June 30, 2026
BridgeBio Oncology Therapeutics trades at a -38.22% free-cash-flow yield. That FCF yield is higher than 43% of its own month-end history back to 2024.
Earnings yield -45.93%.
21 month-end valuation observations are on file, starting December 2024.
Sector comparison uses 2682 Healthcare names.
Frequently asked questions
Is BBOT cheap versus its own history?
BridgeBio Oncology Therapeutics trades at a -38.22% free-cash-flow yield. That FCF yield is higher than 43% of its own month-end history back to 2024.
What is BBOT's free-cash-flow yield?
BridgeBio Oncology Therapeutics currently yields -38.22% of market cap as trailing free cash flow.
Where do these valuation figures come from?
Yields and quality metrics are computed from the same SEC TTM figures as the financials page, against the live market cap. Historical bands reconstruct month-end market cap from split-adjusted closes and the share count in the units it was filed, then divide by those dollar totals. Nothing here is a third-party estimate.